VYNE VYNE Therapeutics Inc
11,010
$2.75
$0.14
(4.84%)
| Watchers | 11,010 |
| 52-Wk Low | $1.67 |
| 52-Wk High | $7.88 |
| Market Cap | $40.75M |
| Volume | 1,937.00 |
| 52-Wk High | $7.88 |
| 52-Wk Low | $1.67 |
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobe Newswire • about 2 months ago
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company focused on developing proprietary...
Share to Feed
VYNE Therapeutics Inc. (NASDAQ:VYNE Get Free Report) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 35,800...
Vyne Therapeutics files for $250M mixed shelf...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional...
Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq...
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company developing proprietary, innovative...
Insiders who bought US$125.5k worth of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) stock in the last year have seen some of...
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201's rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...